{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-003178","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2022-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.895403+00:00","generated_at":"2026-06-27T06:35:31.771849+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Avalo Therapeutics promotes Garry Neil to CEO and Chris Sullivan to CFO, replaces Cola and Greenway","bullets":["Garry Neil appointed CEO from CSO; base salary $475K/yr, option for 1M shares vesting 4 years.","Chris Sullivan appointed CFO from CAO; base salary $350K/yr, $50K bonus, option for 400K shares.","Former CEO Michael Cola and CFO Schond Greenway terminated effective Feb 14, 2022.","Neil serves as Chairman of Arena Pharmaceuticals (ARNA), a ~$6B Nasdaq biotech.","Sullivan previously helped raise ~$80M in gross proceeds as interim CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-003178","json":"https://secwatch.observer/filing/0001628280-22-003178.json","markdown":"https://secwatch.observer/filing/0001628280-22-003178.md","text":"https://secwatch.observer/filing/0001628280-22-003178.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022003178/0001628280-22-003178-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022003178/avtx-20220214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T06:35:31.771849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"767cd06b06","claim":"Christopher Sullivan was appointed as Chief Financial Officer at Avalo Therapeutics, Inc..","evidence_excerpt":"On February 14, 2022, the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Garry A. Neil as President and Chief Executive Officer of the Company and Christopher Sullivan as Chief Financial Officer, effective February 14, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022003178/0001628280-22-003178-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e422d09b5e","claim":"Garry A. Neil was appointed as President and Chief Executive Officer at Avalo Therapeutics, Inc..","evidence_excerpt":"On February 14, 2022, the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Garry A. Neil as President and Chief Executive Officer of the Company and Christopher Sullivan as Chief Financial Officer, effective February 14, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022003178/0001628280-22-003178-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}